Loading…
Xenetic Biosciences, Inc. is projected to rise to $3.68 by 2027, a +34% move from its current price of $2.74. XBIO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $2.65 | $2.74 | $2.82 | 0.00% |
| Jul 14 | $2.62 | $2.74 | $2.86 | +0.01% |
| Jul 15 | $2.59 | $2.74 | $2.88 | +0.01% |
| Jul 16 | $2.57 | $2.74 | $2.91 | +0.02% |
| Jul 17 | $2.55 | $2.74 | $2.93 | +0.02% |
| Jul 18 | $2.54 | $2.74 | $2.95 | +0.03% |
| Jul 19 | $2.52 | $2.74 | $2.97 | +0.03% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.52 | $2.74 | $2.97 | +0.03% |
| Week 2 | $2.44 | $2.74 | $3.07 | +0.07% |
| Week 3 | $2.38 | $2.74 | $3.15 | +0.10% |
| Week 4 | $2.33 | $2.74 | $3.22 | +0.13% |
| Week 5 | $2.29 | $2.74 | $3.28 | +0.17% |
| Week 6 | $2.25 | $2.74 | $3.34 | +0.20% |
| Week 7 | $2.21 | $2.74 | $3.40 | +0.24% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance.
The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC.
Xenetic Biosciences is headquartered in Framingham, Massachusetts.
XBIO trades around $2.80 per share and has a market capitalization of $6.41M, ranking 5264. The stock shows a neutral near-term technical backdrop with RSI(14) at 50. The 30-day price range runs from $2.28 to $3.44, with a nearby support at $2.84 and resistance at $3.43.
The market remains sensitive to broader swings given an annualized volatility of 60% and a neutral sentiment overall. The longer-term forecast envisions substantial appreciation, with 2026 average price $2.80, 2030 average $5.63, 2040 average $14.72 and 2050 average $29.16, while maximum targets climb to $3.97 (2026), $8.43 (2030), $25.99 (2040) and $56.77 (2050).
A major floor 18.2% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.9% away) — a key level to hold.
The nearest ceiling, 25.4% above — a clean break opens room to run.
A major ceiling 34.5% above — clearing it would confirm fresh momentum.
Key XBIO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of XBIO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.79 | Sell | $2.78 | Sell |
| MA 10 | $2.84 | Sell | $2.82 | Sell |
| MA 20 | $2.91 | Sell | $2.89 | Sell |
| MA 50 | $3.02 | Sell | $2.96 | Sell |
| MA 100 | $2.93 | Sell | $2.93 | Sell |
| MA 200 | $2.92 | Sell | $2.96 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.59 | Neutral |
| Stoch RSI (14) | 23.31 | Neutral |
| CCI (20) | -113.95 | Sell |
| Williams %R (14) | -89.36 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -5.69 | Sell |
| Bollinger %B (20,2) | 0.18 | Neutral |
| Stochastic %K (14) | 10.64 | Buy |
| TRIX (15) | -0.32 | Sell |
| Awesome (5,34) | -0.22 | Sell |
| Ultimate (7,14,28) | 39.79 | Neutral |
| Momentum (10) | -0.09 | Sell |
| Aroon Osc (25) | -88.00 | Sell |
| Hull MA (9) | 2.73 | Buy |
| ADX (14) | 12.45 | Neutral |
| ATR (14) | 0.09 | Info |
Near-term sentiment is neutral. RSI(14) sits at 50, and the 50-day and 200-day moving averages stand at $3.13 and $2.95 respectively, offering a modest bullish cross signal if prices hold above the nearer SMA. Immediate support sits at $2.84, with resistance at $3.43, framing a 30-day range of $2.28 to $3.44.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.08 | $2.74 | $3.60 | 0% | Neutral | |
| $2.89 | $3.68 | $4.96 | +34% | Bullish | |
| $2.98 | $3.91 | $5.49 | +43% | Bullish | |
| $3.14 | $4.23 | $6.14 | +55% | Bullish | |
| $3.28 | $4.52 | $6.73 | +65% | Bullish | |
| $3.08 | $4.34 | $6.63 | +59% | Bullish | |
| $3.18 | $4.57 | $7.12 | +67% | Bullish | |
| $3.66 | $5.36 | $8.51 | +96% | Bullish | |
| $4.43 | $6.60 | $10.65 | +141% | Bullish | |
| $4.66 | $7.06 | $11.59 | +158% | Bullish | |
| $5.60 | $9.18 | $16.11 | +236% | Bullish | |
| $9.24 | $17.37 | $33.57 | +535% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.08 | $2.74 | $3.29 | +0.00% |
| August 2026 | $2.27 | $2.69 | $3.28 | -1.70% |
| September 2026 | $2.30 | $2.75 | $3.39 | +2.17% |
| October 2026 | $2.42 | $2.90 | $3.62 | +5.65% |
| November 2026 | $2.40 | $2.90 | $3.65 | +0.08% |
| December 2026 | $2.34 | $2.84 | $3.60 | -2.07% |
Click any year to see its month-by-month XBIO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The XBIO price prediction for 2026 points to an average of $2.74 (low $2.08, high $3.60) — a potential gain of 0% on today's $2.74. A consolidation phase looks the most probable path here.
In 2027, XBIO is projected to trade between $2.89 and $4.96, averaging $3.68 — a potential gain of +34% from today's $2.74. That is up +34% on the projected 2026 average. Momentum favours further upside here.
Xenetic Biosciences, Inc.'s 2028 outlook centres on $3.91, within a $2.98 to $5.49 range. That is up +6% on the projected 2027 average. That marks a +43% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, XBIO could reach as high as $6.14, with a base case around $4.23 and support toward $3.14 — roughly +55% from $2.74. Momentum favours further upside here.
Expect XBIO to range from $3.28 to $6.73 through 2030. The $4.52 average target implies a +65% move from current prices. That is up +7% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The XBIO price prediction for 2031 points to an average of $4.34 (low $3.08, high $6.63) — a potential gain of +59% on today's $2.74. Momentum favours further upside here.
In 2032, XBIO is projected to trade between $3.18 and $7.12, averaging $4.57 — a potential gain of +67% from today's $2.74. That is up +5% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Xenetic Biosciences, Inc.'s 2033 outlook centres on $5.36, within a $3.66 to $8.51 range. That is up +17% on the projected 2032 average. That marks a +96% change versus current levels. Momentum favours further upside here.
By 2034, XBIO could reach as high as $10.65, with a base case around $6.60 and support toward $4.43 — roughly +141% from $2.74. Buyers look set to stay in control over this stretch.
Expect XBIO to range from $4.66 to $11.59 through 2035. The $7.06 average target implies a +158% move from current prices. That is up +7% on the projected 2034 average. Momentum favours further upside here.
The XBIO price prediction for 2040 points to an average of $9.18 (low $5.60, high $16.11) — a potential gain of +236% on today's $2.74. Buyers look set to stay in control over this stretch.
In 2050, XBIO is projected to trade between $9.24 and $33.57, averaging $17.37 — a potential gain of +535% from today's $2.74. That is up +89% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in XBIO today (≈ 365.630713 XBIO) could be worth
$6,350.54
+$5,350.54 (+535%) by 2050 · US Dollar
Based on the average projected XBIO price of $17.37 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in XBIOwould be worth at today's price.
$1,000 invested in XBIO on Jul 10, 2025 (≈ 260.960333 XBIO) would be worth
$713.73
-$286.27 (-28.6%) today · 0.71× · US Dollar
Based on a XBIO entry price of $3.83 vs. today's $2.74.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.77 | $987.36 | -1.3% |
| 1 month ago | $3 | $911.67 | -8.8% |
| 3 months ago | $3.06 | $893.79 | -10.6% |
| 6 months ago | $2.3 | $1,191.2 | +19.1% |
| 1 year ago | $3.83 | $713.73 | -28.6% |
| All time (5.0y) ago | $24.6 | $111.18 | -88.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our XBIO forecast.
Our base-case forecast reaches $5.50 around 2034.
Implied market cap at $5.50: $12.6M
The multi-year forecast shows a bullish trajectory from 2027 onward, with 2027 average price $4.18 and ROI 49.3, 2028 average $4.40 and ROI 57.1, and 2029 average $5.10 with ROI 82.3. The 2030 forecast yields an average of $5.63 and an ROI of 101, while 2031–2035 continue the ascent (2031 avg $5.29, ROI 89; 2032 avg $6.29, ROI 124.8; 2033 avg $7.92, ROI 182.7; 2034 avg $9.17, ROI 227.5; 2035 avg $10.22, ROI 264.9). The long-range nodes show continued strength, with 2040 average $14.72 and ROI 425.9, and 2050 average $29.16 and ROI 941.6.
Max price targets rise from $3.97 in 2026 to $56.77 in 2050. These projections imply meaningful upside but remain uncertain and are not guarantees. Investors should consider the high volatility reflected in the 60% annualized volatility and the inherent risk in biotechnology equities.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $5.63 with a range from $4.06 to $8.43 and a projected ROI of 101%. The sentiment is bullish.
The forecast indicates bullish sentiment from 2027 onward, with average prices rising to $5.63 in 2030, $14.72 in 2040 and $29.16 in 2050, and maximum targets up to $56.77. These are estimates, not guarantees.
Yes—the forecast maximum price by 2050 is $56.77, which exceeds 50. This projection is not a guarantee and depends on future conditions.
Current price is $2.80 and market capitalization is $6.41M.
2026 average $2.80; 2030 average $5.63; 2040 average $14.72; 2050 average $29.16, with max targets of $3.97, $8.43, $25.99, and $56.77 respectively. The outlook shows bullish potential, but remains uncertain.
Xenetic Biosciences, Inc. Community Discussion
0Share your Xenetic Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.